CA2137832A1 - Inhibitors of Angiotensin I Chymase(s) Including Human Heart Chymase - Google Patents

Inhibitors of Angiotensin I Chymase(s) Including Human Heart Chymase

Info

Publication number
CA2137832A1
CA2137832A1 CA 2137832 CA2137832A CA2137832A1 CA 2137832 A1 CA2137832 A1 CA 2137832A1 CA 2137832 CA2137832 CA 2137832 CA 2137832 A CA2137832 A CA 2137832A CA 2137832 A1 CA2137832 A1 CA 2137832A1
Authority
CA
Canada
Prior art keywords
chymase
angiotensin
inhibitors
including human
human heart
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA 2137832
Other languages
French (fr)
Other versions
CA2137832C (en
Inventor
Dennis J. Hoover
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Dennis J. Hoover
Pfizer Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dennis J. Hoover, Pfizer Limited filed Critical Dennis J. Hoover
Publication of CA2137832A1 publication Critical patent/CA2137832A1/en
Application granted granted Critical
Publication of CA2137832C publication Critical patent/CA2137832C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A compound of formula (I) which is effective for treating or preventing hypertension, congestive heart failure myocardial infarction, cardiac and left ventricular hypertrophy, coronary artery disease including myocardial infarction, vascular hypertrophy, and vascular damage following diabetic and non-diabetic renal disease, and vascular damage associated with angioplasty and aetheroma.
CA002137832A 1992-06-12 1993-04-23 Inhibitors of angiotensin i chymase(s) including human heart chymase Expired - Fee Related CA2137832C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US89772392A 1992-06-12 1992-06-12
US897,723 1992-06-12
PCT/US1993/003625 WO1993025574A1 (en) 1992-06-12 1993-04-23 Inhibitors of angiotensin i chymase(s) including human heart chymase

Publications (2)

Publication Number Publication Date
CA2137832A1 true CA2137832A1 (en) 1993-12-23
CA2137832C CA2137832C (en) 2000-09-26

Family

ID=25408314

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002137832A Expired - Fee Related CA2137832C (en) 1992-06-12 1993-04-23 Inhibitors of angiotensin i chymase(s) including human heart chymase

Country Status (5)

Country Link
EP (1) EP0644892A1 (en)
JP (1) JP2668003B2 (en)
CA (1) CA2137832C (en)
FI (1) FI932695A (en)
WO (1) WO1993025574A1 (en)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9524267D0 (en) * 1995-11-28 1996-01-31 Isis Innovation Enzyme inhibitor and method
CZ82399A3 (en) * 1996-09-10 1999-06-16 Dr. Karl Thomae Gmbh Modified amino acids , process of their preparation and pharmaceutical composition containing thereof
NZ335276A (en) 1996-10-18 2000-09-29 Vertex Pharma Inhibitors of serine proteases, particularly hepatitis C virus (HCV) NS3 (Non Structural Protein 3) protease
SI0932617T1 (en) * 1996-10-18 2002-06-30 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
WO1998018794A1 (en) * 1996-10-25 1998-05-07 Yoshitomi Pharmaceutical Industries, Ltd. Novel heterocyclic amide compounds and medicinal uses thereof
US20030069231A1 (en) * 1999-10-12 2003-04-10 Klaus Rudolf Modified aminoacids, pharmaceuticals containing these compounds and method for their production
AU744739B2 (en) * 1998-02-17 2002-02-28 Nippon Kayaku Kabushiki Kaisha Novel acetamide derivative and use thereof
KR20010074838A (en) * 1998-08-20 2001-08-09 요시다 쇼지 Preventives or remedies for eye circulatory failure
EP1136488A4 (en) * 1998-12-01 2002-06-12 Meiji Seika Kaisha Sf2809-i, ii, iii, iv, v and vi substances exhibiting chymase-inhibiting activities
CN1335778A (en) 1999-11-01 2002-02-13 三得利株式会社 Inhibitors against vascular lipid deposition containing chymase-inhibiting substances
KR20010109356A (en) 2000-02-22 2001-12-08 도리이 신이치로 Preventive or therapeutic drugs for dermatitises containing chymase inhibitors as the active ingredient
CA2368366A1 (en) 2000-02-22 2001-08-30 Suntory Limited Medicament for prevention or treatment of fibrosis having chymase inhibitor as effective ingredient
AU3413501A (en) 2000-02-22 2001-09-03 Daiichi Asubio Pharma Co., Ltd. Preventive or therapeutic drugs for various eosinophilia-related diseases containing chymase inhibitors as the active ingredient
CA2411165A1 (en) * 2000-05-02 2002-12-11 Meiji Seika Kaisha, Ltd. Novel indole derivatives exhibiting chymase-inhibitory activities and process for preparation thereof
AU2002222933A1 (en) * 2000-07-13 2002-01-30 Millennium Pharamaceuticals, Inc. Inhibitors of factor xa
GB0021315D0 (en) 2000-08-30 2000-10-18 Dainippon Pharmaceutical Co Heterocyclic compounds and intermediates thereof
US6982348B2 (en) 2001-01-26 2006-01-03 Takeda Pharmaceutical Company Limited Aminoethanol derivatives
GB0205166D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205170D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205176D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205162D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205165D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205175D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
US7595312B2 (en) 2002-10-25 2009-09-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions
KR101187693B1 (en) 2003-05-09 2012-10-05 도레이 카부시키가이샤 Agent for treating or preventing renal disease
MY148123A (en) 2003-09-05 2013-02-28 Vertex Pharma Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
DE102004015723A1 (en) 2004-03-29 2005-10-20 Boehringer Ingelheim Pharma Selected CGRP antagonists, process for their preparation and their use as pharmaceuticals
EP2374812B1 (en) 2006-07-13 2015-04-15 Achillion Pharmaceuticals, Inc. 4-amino-4-oxobutanoyl Peptides as Inhibitors of Viral Replication
AU2009324643B2 (en) 2008-12-10 2014-08-28 Achillion Pharmaceuticals, Inc. New 4-amino-4-oxobutanoyl peptides as inhibitors of viral replication
KR20160005686A (en) 2013-03-15 2016-01-15 아칠리온 파르마세우티칼스 인코포레이티드 Sovaprevir polymorphs and methods of manufacture thereof
US9085607B2 (en) 2013-03-15 2015-07-21 Achillion Pharmaceuticals, Inc. ACH-0142684 sodium salt polymorph, composition including the same, and method of manufacture thereof
JP7164521B2 (en) 2016-06-21 2022-11-01 オリオン・オフサルモロジー・エルエルシー carbocyclic prolinamide derivatives
EA201990069A1 (en) 2016-06-21 2019-06-28 ОРИОН ОФТАЛМОЛОДЖИ ЭлЭлСи DERIVATIVES OF HETEROCYCLIC PROLINAMIDE

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4499082A (en) * 1983-12-05 1985-02-12 E. I. Du Pont De Nemours And Company α-Aminoboronic acid peptides
CA2021660A1 (en) * 1989-07-26 1991-01-27 Philippe Bey Peptidase inhibitors
WO1992020357A1 (en) * 1991-05-23 1992-11-26 Merrell Dow Pharmaceuticals Inc. Inhibitors of cathepsin g and elastase for preventing connective tissue degradation

Also Published As

Publication number Publication date
FI932695A (en) 1993-12-13
JP2668003B2 (en) 1997-10-27
EP0644892A1 (en) 1995-03-29
FI932695A0 (en) 1993-06-11
JPH07507069A (en) 1995-08-03
CA2137832C (en) 2000-09-26
WO1993025574A1 (en) 1993-12-23

Similar Documents

Publication Publication Date Title
CA2137832A1 (en) Inhibitors of Angiotensin I Chymase(s) Including Human Heart Chymase
CA2286272A1 (en) Surgical retractor
WO1991000281A3 (en) Fused-ring aryl substituted imidazoles
CA2166983A1 (en) Determining hemodynamic variables from a pressure sensor
CA2385997A1 (en) Surgical retractor
CA2275221A1 (en) Side access "over the wire" pacing lead
WO2002071974A3 (en) A stent for arterialization of the coronary sinus and retrograde perfusion of the myocardium
EP0487745A4 (en) Pyridine derivative with angiotensin ii antagonism
DE69407785T2 (en) BENZOYLBENZOFURANE DERIVATIVES FOR THE TREATMENT OF HEART ARRHYTHMIA
CA2030263A1 (en) Implantable pharmacological defibrillator with automatic recognition of ventricular fibrillation
WO2001028992A3 (en) New oxabispidine compounds useful in the treatment of cardiac arrhythmias
WO1996024348A3 (en) Use of carbazole compounds for the treatment of congestive heart failure
CA2134972A1 (en) Anti-ischemic medicament
EP1125580A3 (en) Methods of treating diabetic cardiomyopathy using glycogen phosphorylase inhibitors
CA2055637A1 (en) Method for the treatment of cardiac and of vascular hypertrophy and hyperplasia
CA2182062A1 (en) Substituted cinnamic acid guanidides, a process for their preparation, their use as medicaments or diagnostic agents, and medicaments comprising them
CA2182477A1 (en) Pyridyl Imidazole Derivatives and Processes for the Preparation Thereof
Szatmary et al. The combined use of diastolic counterpulsation and coronary dilation in unstable angina due to multivessel disease under unstable hemodynamic conditions
TW222275B (en)
KUCK et al. Pleomorphic ventricular tachycardia: demonstration of conduction reversal within the reentry circuit
MX9604019A (en) Biothyne derivatives.
DE59405893D1 (en) Linear adhesion inhibitors
AU1855088A (en) Treating agent for heart failure
EP0362152A3 (en) Use of 3-indolepyruvic acid as a pharmaceutical agent for the inhibition of peripheral degenerative pathologies
Yasuda et al. Hyposecretion of trial natriuretic peptide due to associated right atrial infarction in a patient with acute right ventricular infarction?

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed